These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 8081030)
1. [Biphosphonates and multiple myeloma]. Mazières B; Laroche M; Cantagrel A Bull Cancer; 1993; 80(10 Suppl):45-9. PubMed ID: 8081030 [No Abstract] [Full Text] [Related]
2. [Biphosphonates in oncology]. Khosravi Shahi P; Díaz Muñoz de la Espada V An Med Interna; 2005 Nov; 22(11):544-7. PubMed ID: 16454591 [TBL] [Abstract][Full Text] [Related]
4. [Bisphosphonates in the therapy of cancer patients]. Jantunen E; Kumpulainen E Duodecim; 1999; 115(1):27-32. PubMed ID: 11830857 [No Abstract] [Full Text] [Related]
5. Bisphosphonates--role in cancer therapies. Mehrotra B J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):19-26. PubMed ID: 19371811 [No Abstract] [Full Text] [Related]
6. Bisphosphonates may potentiate effects of thalidomide-dexamethasone combination in advanced multiple myeloma. Ural AU; Avcu F Am J Hematol; 2006 May; 81(5):385-6; author reply 386. PubMed ID: 16628715 [No Abstract] [Full Text] [Related]
7. Metastatic bone disease and the role of bisphosphonates. Ellis MJ Br J Hosp Med; 1996 Oct 2-15; 56(7):339-45. PubMed ID: 8899222 [No Abstract] [Full Text] [Related]
8. Bisphosphonates in multiple myeloma: current status; future perspectives. Jantunen E; Laakso M Br J Haematol; 1996 Jun; 93(3):501-6. PubMed ID: 8652366 [No Abstract] [Full Text] [Related]
9. [Biphosphonates in the treatment of osteolytic metastasis. Essential actions on hypercalcemia and important on lytic lesions]. Liens D; Delmas PD Rev Prat; 1993 May; 43(10):1259-61. PubMed ID: 8235365 [No Abstract] [Full Text] [Related]
10. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Body JJ; Greipp P; Coleman RE; Facon T; Geurs F; Fermand JP; Harousseau JL; Lipton A; Mariette X; Williams CD; Nakanishi A; Holloway D; Martin SW; Dunstan CR; Bekker PJ Cancer; 2003 Feb; 97(3 Suppl):887-92. PubMed ID: 12548591 [TBL] [Abstract][Full Text] [Related]
11. Disodium pamidronate for treating severe hypercalcemia in a hemodialysis patient. Trimarchi H; Lombi F; Forrester M; Elizondo C; Sawinski D; Pereyra H; Freixas E Nat Clin Pract Nephrol; 2006 Aug; 2(8):459-63; quiz 464. PubMed ID: 16932480 [TBL] [Abstract][Full Text] [Related]
12. Secretion of parathyroid hormone-related peptide in patients with multiple myeloma. Beaudreuil J; Cohen-Solal M; Doré MX; Vernejoul MC; Bardin T; Celton N; Giraudeaux V; Kuntz D Rev Rhum Engl Ed; 1996; 63(7-8):502-3. PubMed ID: 8896065 [TBL] [Abstract][Full Text] [Related]
13. [Bisphosphonates in the treatment of multiple myeloma]. Stajszczyk M Przegl Lek; 2002; 59(1):37-42. PubMed ID: 12108045 [TBL] [Abstract][Full Text] [Related]
14. The role of bisphosphonates in multiple myeloma. Kyle RA Ann Intern Med; 2000 May; 132(9):734-6. PubMed ID: 10787368 [No Abstract] [Full Text] [Related]
16. Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer. Paterson AH; Kanis JA; Powles TJ; McCloskey E; Hanson J; Ashley S Can J Oncol; 1995 Dec; 5 Suppl 1():54-7. PubMed ID: 8853526 [TBL] [Abstract][Full Text] [Related]
17. FDA approves ZOMETA for treatment of cancer-related bone complications. Expert Rev Anticancer Ther; 2002 Apr; 2(2):137-8. PubMed ID: 12113230 [No Abstract] [Full Text] [Related]
18. Bone disease in multiple myeloma: new markers, new treatments. Joshua D Intern Med J; 2001 Jul; 31(5):261-3. PubMed ID: 11512595 [No Abstract] [Full Text] [Related]
20. In vitro and in vivo antiresorptive effects of bisphosphonates in metastatic bone disease. Kanakis I; Kousidou OCh; Karamanos NK In Vivo; 2005; 19(1):311-8. PubMed ID: 15796191 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]